Evidence map›Paper›PMID 39225829›Full record

ReviewNaunyn-Schmiedeberg's archives of pharmacology2025

Can infliximab serve as a new therapy for neuropsychiatric symptoms?

Fatemeh Rahmati-Dehkordi, Nafiseh Birang, Mohammad Naser Jalalian, Zeinab Tamtaji, Ehsan Dadgostar, Michael Aschner, Mehdi Shafiee Ardestani, Hamed Jafarpour, Hamed Mirzaei, Fatemeh Nabavizadeh and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Fatemeh Rahmati-DehkordiStudents' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Nafiseh BirangDepartment of Physical Medicine and Rehabilitation, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohammad Naser JalalianFaculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Zeinab TamtajiStudent Research Committee, Kashan University of Medical Sciences, Kashan, Iran.
Ehsan DadgostarBehavioral Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Michael AschnerDepartment of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA.
Mehdi Shafiee ArdestaniDepartment of Radio Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Hamed JafarpourFaculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Hamed MirzaeiResearch Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran. h.mirzaei2002@gmail.com.
Fatemeh NabavizadehElectrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. Nabavizadeh@tums.ac.ir.
Omid Reza TamtajiElectrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. tamtaji.or@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuropsychiatric disorders present a global challenge to public health. Mechanisms associated with neuropsychiatric disorders etiology include apoptosis, oxidative stress, and neuroinflammation. Tumor necrosis factor alpha, an inflammatory cytokine, mediates pathophysiology of neuropsychiatric disorders. Therefore, its inhibition by infliximab might afford a valuable target for intervention. Infliximab is commonly used to treat inflammatory diseases, including ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Recently, it has been shown that infliximab improves cognitive dysfunction, depression, anxiety, and life quality. Here, we review contemporary knowledge supporting the need to further characterize infliximab as a potential treatment for neuropsychiatric disorders.

Indexed as

InfliximabMental DisordersAnimalsHumansTumor Necrosis Factor-alphaInfliximabTumor Necrosis Factor-alphaCognitionDepressionInflammationInfliximabNeuropsychiatric disorders

Identifiers

PMID39225829

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.